
GHRS Stock Forecast & Price Target
GHRS Analyst Ratings
Bulls say
GH Research is expected to continue its positive momentum as they approach initiation of their pivotal Phase 3 trial for GH001 in treatment-resistant depression (TRD). The company's recent achievements, such as publishing positive Phase 2b results and completing enrollment in Phase 1 trials, demonstrate progress towards their goal of developing a practice-changing treatment for depression. With a strong portfolio and a healthy cash balance, GH Research has the potential to be a leader in the biopharmaceutical industry and create significant value for investors.
Bears say
GH Research is a clinical-stage biopharmaceutical company focused on developing mebufotenin therapies for Treatment-Resistant Depression (TRD). With only a single segment of Research and Development, and a lack of meaningful competitive programs in China, there may be limited potential for revenue growth. Additionally, the company's decision to keep details of their aerosolized device/dosing regimen secret for competitive reasons may indicate potential issues or concerns.
This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.
GHRS Analyst Forecast & Price Prediction
Start investing in GHRS
Order type
Buy in
Order amount
Est. shares
0 shares